You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

CLINICAL TRIALS PROFILE FOR TEDUGLUTIDE RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Teduglutide Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00081458 ↗ Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Completed Shire Phase 3 2004-05-25 The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).
NCT00172185 ↗ Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed Shire Phase 3 2005-01-10 The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
NCT00308438 ↗ Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 Completed Shire Phase 2 2004-03-01 The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teduglutide Recombinant

Condition Name

Condition Name for Teduglutide Recombinant
Intervention Trials
Short Bowel Syndrome 18
Hyperlipidemias 4
Healthy Volunteers 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Teduglutide Recombinant
Intervention Trials
Syndrome 18
Short Bowel Syndrome 18
Hyperlipoproteinemias 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Teduglutide Recombinant

Trials by Country

Trials by Country for Teduglutide Recombinant
Location Trials
United States 110
Canada 22
Japan 18
United Kingdom 16
Germany 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Teduglutide Recombinant
Location Trials
New York 10
Ohio 9
California 7
Pennsylvania 7
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Teduglutide Recombinant

Clinical Trial Phase

Clinical Trial Phase for Teduglutide Recombinant
Clinical Trial Phase Trials
Phase 4 3
Phase 3 17
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Teduglutide Recombinant
Clinical Trial Phase Trials
Completed 28
Active, not recruiting 3
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Teduglutide Recombinant

Sponsor Name

Sponsor Name for Teduglutide Recombinant
Sponsor Trials
Shire 21
Takeda 4
University Health Network, Toronto 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Teduglutide Recombinant
Sponsor Trials
Industry 32
Other 18
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Teduglutide Recombinant: Clinical Trials, Market Analysis, and Projections

Introduction

Teduglutide, a recombinant analog of the human glucagon-like peptide-2 (GLP-2), has been a significant advancement in the management of short bowel syndrome (SBS) and intestinal failure. Here, we will delve into the current status of clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

Phase 3 and 4 Trials

Teduglutide has undergone extensive clinical trials to evaluate its efficacy and safety in patients with SBS. The STEPS trial, a Phase III randomized double-blinded controlled study, demonstrated that teduglutide significantly reduced the volume of parenteral nutrition (PN) required by patients. A clinically meaningful response, defined as a 20-100% reduction in PN volume, was achieved in 63% of the treatment group compared to 30% in the placebo group[4].

Recent Phase 3 trials have also focused on pediatric patients. For instance, a study in Japanese pediatric patients with SBS who are dependent on parenteral support showed that teduglutide was generally well-tolerated, with adverse events in line with known impacts of SBS and teduglutide[1].

Safety and Adverse Reactions

Clinical trials have identified several adverse reactions associated with teduglutide. Common adverse events include mild abdominal pain, stoma changes, and redness at the injection site. More serious adverse reactions reported in the post-marketing phase include cardiac arrest, cardiac failure, cholecystitis, cholangitis, and acute pancreatitis[2].

Pharmacokinetics and Dosing

The pharmacokinetics of teduglutide have been evaluated in both healthy subjects and those with SBS. The drug is absorbed with a peak concentration at 3-5 hours after subcutaneous administration. Patients with renal impairment may require a dose reduction due to increased drug exposure[5].

Market Analysis

Current Market Size and Growth

The global teduglutide market was valued at USD 50 billion in 2023 and is projected to reach USD 97.4 billion by 2031, growing at a compound annual growth rate (CAGR) of 10% from 2024 to 2031. This growth is driven by increasing awareness of viable treatments for SBS, advancements in medication delivery technologies, and favorable regulatory frameworks[3].

Market Segmentation

The teduglutide market is segmented based on application (injections, vials, lyophilized powder, prefilled syringes, cartridges) and product (short bowel syndrome, parenteral nutrition, pediatric short bowel syndrome, intestinal failure, chronic intestinal pseudo-obstruction). Geographical regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa are also key segments[3].

Competitive Landscape

The competitive landscape of the teduglutide market involves various pharmaceutical companies and research institutions. Strategic alliances and collaborations among these entities are enhancing the drug's accessibility and distribution networks, thereby accelerating its market penetration. A Porter’s Five Forces analysis highlights the bargaining power of buyers and suppliers, the threat of new entrants, the threat of substitutes, and the degree of competition in the market[3].

Market Projections

Increasing Prevalence of SBS

The rising prevalence of short bowel syndrome and the growing need for efficient therapies are major factors propelling the teduglutide market. As awareness and diagnosis of SBS improve, the demand for teduglutide is expected to increase significantly[3].

Advancements in Biotechnology and Pharmaceutical Research

Developments in biotechnology and pharmaceutical research are facilitating the creation of better teduglutide formulations, which will enhance the medication's effectiveness and patient compliance. These advancements are expected to contribute to the market's robust growth[3].

Regulatory and Reimbursement Support

Favorable reimbursement rules and government programs that fund therapies for rare diseases are supporting the growth of the teduglutide market. Increased investment in healthcare infrastructure and awareness campaigns concerning SBS are also ensuring improved patient outcomes and treatment options[3].

Key Takeaways

  • Clinical Efficacy: Teduglutide has demonstrated significant efficacy in reducing the volume of parenteral nutrition required by patients with SBS.
  • Safety Profile: While generally well-tolerated, teduglutide is associated with several adverse reactions that need careful monitoring.
  • Market Growth: The global teduglutide market is expected to grow at a CAGR of 10% from 2024 to 2031, driven by increasing awareness, technological advancements, and favorable regulatory frameworks.
  • Market Segmentation: The market is segmented based on application, product, and geographical regions, with North America and Europe being key markets.
  • Competitive Landscape: Strategic alliances and collaborations among pharmaceutical companies are enhancing the drug's accessibility and distribution.

FAQs

What is teduglutide and how does it work?

Teduglutide is a recombinant analog of the human glucagon-like peptide-2 (GLP-2). It works by enhancing intestinal nutrient bioavailability through intestinotrophic effects, increasing villus height and crypt depth, and decreasing gastric motility and intestinal secretory losses[2].

What are the common adverse reactions associated with teduglutide?

Common adverse reactions include mild abdominal pain, stoma changes, and redness at the injection site. More serious adverse reactions include cardiac arrest, cardiac failure, cholecystitis, cholangitis, and acute pancreatitis[2].

What is the current market size of teduglutide and its projected growth?

The global teduglutide market was valued at USD 50 billion in 2023 and is projected to reach USD 97.4 billion by 2031, growing at a CAGR of 10% from 2024 to 2031[3].

How does teduglutide impact the management of short bowel syndrome?

Teduglutide offers a new targeted approach to SBS-associated intestinal failure management by reducing the volume of parenteral nutrition required, thereby improving the quality of life for patients with SBS[4].

What are the key factors driving the growth of the teduglutide market?

Key factors include increasing awareness of viable treatments for SBS, advancements in medication delivery technologies, favorable regulatory frameworks, and growing investment in healthcare infrastructure[3].

Are there any specific dosing considerations for patients with renal impairment?

Yes, patients with moderate to severe renal impairment or end-stage renal disease may require a dose reduction of teduglutide due to increased drug exposure[5].

Sources

  1. Patsnap: Teduglutide Recombinant - Drug Targets, Indications, Patents.
  2. Australian Government Department of Health and Aged Care: Australian public assessment for Teduglutide [Revestive].
  3. Market Research Intellect: Teduglutide Market Size, Share | Industry Research Report 2031.
  4. PubMed: Study of teduglutide effectiveness in parenteral nutrition ... - PubMed.
  5. FDA: 203441Orig1s000 - accessdata.fda.gov.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.